Cambridge, Mass.– Repare Therapeutics, a clinical-stage precision oncology company, has out-licensed its suite of discovery platforms to DCx Biotherapeutics, a newly launched Canadian biotech firm focused on developing next-generation precision drug conjugates.
The agreement, announced Wednesday, includes the transfer of intellectual property related to Repare’s discovery technologies, as well as select research personnel, lab facilities, and equipment in Montreal. The transaction allows Repare to streamline operations and focus on its clinical-stage drug development programs.
“This strategic move enables us to reduce costs while maintaining an economic stake in our platform technologies,” said Steve Forte, Repare’s president, CEO, and CFO. “It’s part of our ongoing effort to align resources with our highest-value opportunities, particularly our two Phase 1 clinical trials, from which we expect to report data in the second half of 2025.”
As part of the deal, Repare will receive $4 million in upfront and near-term payments, a 9.99% equity stake in DCx—with anti-dilution protections—and eligibility for milestone payments and tiered royalties on any future product sales developed using the licensed platforms.
DCx Biotherapeutics, backed by Canadian investment firm Amplitude Ventures, will also retain around 20 Repare researchers and gain access to Repare’s SNIPRx, SNIPRx-surf, and STEP2 platforms. These technologies employ advanced genomic screening and machine learning to identify cancer-specific vulnerabilities and surface targets suitable for therapeutic intervention.
Repare will appoint a representative to DCx’s board of directors as part of the agreement, ensuring continued strategic input in the development of the licensed platforms.
